Regression of Metastatic Renal-Cell Carcinoma after Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation

20001,005 citationsJournal Articlebronze Open Access

Authors

Richard Childs · National Institutes of Health

Allen Chernoff

Nathalie Contentin · National Heart Lung and Blood Institute

Erkut Bahceci · National Heart Lung and Blood Institute

David S. Schrump · National Cancer Institute

Susan F. Leitman

Elizabeth J. Read

John F. Tisdale · National Institute of Diabetes and Digestive and Kidney Diseases

Abstract

Nonmyeloablative allogeneic stem-cell transplantation can induce sustained regression of metastatic renal-cell carcinoma in patients who have had no response to conventional immunotherapy.

Topics & Keywords

Hematopoietic Stem Cell Transplantation Renal Transplantation Outcomes and Treatments Polyomavirus and related diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 343, Issue 11, pp. 750-758

DOI: 10.1056/nejm200009143431101

Field-Weighted Citation Impact: 51.17